•  12


    August 2016

    IBM scientists have developed a new lab-on-a-chip technology that can, for the first time, separate biological particles at the nanoscale.

    As reported in the journal Nature Nanotechnology, the IBM team’s results show size-based separation of bioparticles down to 20 nanometres (nm) in diameter, a scale that gives access to important particles such as DNA, viruses and exosomes. This research opens up new avenues of medicine as it could enable scientists to detect diseases such as cancer much earlier than was previously possible.

    ‘The ability to sort and enrich biomarkers at the nanoscale in chip-based technologies opens the door to understanding diseases such as cancer as well as viruses like the ‘flu or Zika,’ said Gustavo Stolovitzky, program director of translational systems biology and nanobiotechnology at IBM Research. ‘Our lab-on-a-chip device could offer a simple, noninvasive and affordable option to detect and monitor a disease, long before physical symptoms manifest. This extra amount of time allows physicians to make more informed decisions and when the prognosis for treatment options is most positive.’

    Until now, the smallest bioparticle that could be separated by size with on-chip technologies was about 50 times or larger, for example, separation of circulating tumour cells from other biological components.

    For the research project, IBM is collaborating with a team from the Icahn School of Medicine at Mount Sinai to continue development of this lab-on-a-chip technology.

    Results from the project show that it is possible to separate and detect particles as small as 20 nm from smaller particles. In addition, the research demonstrates that exosomes of size 100 nm and larger could be separated from smaller exosomes and that separation can take place in spite of diffusion.

    With Mt Sinai, the team plans to confirm their device can pick up exosomes with cancer-specific biomarkers from patient liquid biopsies.

    With the ability to sort bioparticles at the nanoscale, Mt Sinai hopes that IBM’s technology can provide a new method to eavesdrop on the messages carried by exosomes for cell-to-cell communications. This could provide valuable insights into the biology of diseases as well as pave the way to non-invasive diagnostic tools.

    ‘When we are ahead of the disease we usually can address it well; but if the disease is ahead of us, the journey is usually much more difficult. One of the important developments that we are attempting in this collaboration is to have the basic grounds to identify exosome signatures that can be there very early on before symptoms appear or before a disease becomes worse,’ said Dr Carlos Cordon-Cardo, professor and chairman of the Mount Sinai Health System Department of Pathology. ‘By bringing together Mount Sinai’s domain expertise in cancer and pathology with IBM’s systems biology experience and its latest nanoscale separation technology, the hope is to look for specific, sensitive biomarkers in exosomes that represent a new frontier to offering clues that might hold the answer to whether a person has cancer or how to treat it.’

    Lab-on-a-chip technologies have the potential to fundamentally change the way diagnostic tests are carried out as they are often significantly faster, portable, easy to use in addition to requiring less sample volume for a particular test.

    IBM is continuing this research into Lab-on-a-chip technologies, IBM scientists Dr Joshua Smith and Dr Benjamin Wunsch, are currently leading work looking at the use of nanoscale deterministic lateral displacement, or nano-DLD. Using this technology, the IBM researchers are creating lab-on-a-chip technology that allows a liquid sample to be passed, in a continuous flow, through a silicon chip containing an asymmetric pillar array.

    This array allows the system to sort a microscopic stream of nanoparticles, separating particles by size down to a resolution of tens of nanometers. IBM has already managed to scale the chip size to 2cm by 2cm while continuing development to increase the device density to improve functionality and throughput.

    Related site links:

    Nanoscale lateral displacement arrays for the separation of exosomes and colloids down to 20 nm

    IBM Research


    No comments

    Be the first one to leave a comment.

    Post a Comment



    Latest Posts

    Latest Video



    First FDA Approval For Clinical Cloud-Based Deep Learning In Healthcare

     SOURCE: FORBES The first FDA approval for a machine learning application to be used in a clinical setting is a…

    FDA-approved study uses adipose stem cells for treatment of shoulder injuries

    SOURCE Sanford Health is conducting the first clinical trial approved by the FDA to treat injured shoulders using patients’ adipose…

    Could Anatomics BioModel Stereotaxy replace navigation or a robot?

    SOURCE Paul S D’Urso Neurosurgeon & Founder of Anatomics Because 3D printing is so accurate I was able to locate…

    $250 million awarded to new Advanced Robotics Manufacturing Innovation Hub

    SOURCE Headquartered in Pittsburgh, PA, the new institute is made up of governments, industry, academia, and non-profit organizations from across the country….

    Self-assembling 3D printing inks produce more true-to-life tissue

    SOURCE Biological and chemical researchers are developing 3D printable inks capable of self-assembly, i.e. forming a shape based on a…

    Urine Exosomes – An Emerging Trove of Biomarkers

     SOURCE Exosomes are released by most cells and can be isolated from all biofluids including urine. Exosomes are small vesicles…

    What is machine learning?

    SOURCE In this fascinating animation from Oxford Sparks, we take a look at how statistics and computer science can be used to…

    Catalia Health uses social robots to improve health outcomes

    Credit: Catalia Health SOURCE Catalia Health is leading the surge in social robotics, with Mabu, their patient care management system. Catalia…